Related Experiment Video
Updated: Nov 3, 2025
Assaying the Kinase Activity of LRRK2 in vitro
Published on: January 18, 2012
Conformation and dynamics of the kinase domain drive subcellular location and activation of LRRK2
Sven H Schmidt1, Jui-Hung Weng2, Phillip C Aoto2,3
1Department of Biochemistry, University of Kassel, 34132 Kassel, Germany.
Abstract:
To explore how pathogenic mutations of the multidomain leucine-rich repeat kinase 2 (LRRK2) hijack its finely tuned activation process and drive Parkinson's disease (PD), we used a multitiered approach. Most mutations mimic Rab-mediated activation by "unleashing" kinase activity, and many, like the kinase inhibitor MLi-2, trap LRRK2 onto microtubules. Here we mimic activation by simply deleting the inhibitory N-terminal domains and then characterize conformational changes induced by MLi-2 and PD mutations. After confirming that LRRK2RCKW retains full kinase activity, we used hydrogen-deuterium exchange mass spectrometry to capture breathing dynamics in the presence and absence of MLi-2. Solvent-accessible regions throughout the entire protein are reduced by MLi-2 binding. With molecular dynamics simulations, we created a dynamic portrait of LRRK2RCKW and demonstrate the consequences of kinase domain mutations. Although all domains contribute to regulating kinase activity, the kinase domain, driven by the DYGψ motif, is the allosteric hub that drives LRRK2 regulation.
Insights
Pathogenic mutations in leucine-rich repeat kinase 2 (LRRK2) drive Parkinson's disease by altering its activation. The kinase domain acts as an allosteric hub, regulating LRRK2 activity.
Area of Science:
- Biochemistry
- Neuroscience
- Molecular Biology
Background:
- Pathogenic mutations in leucine-rich repeat kinase 2 (LRRK2) are a major genetic cause of Parkinson's disease (PD).
- Understanding LRRK2 activation mechanisms is crucial for developing effective PD therapies.
Purpose of the Study:
- To investigate how pathogenic LRRK2 mutations influence its activation process and contribute to Parkinson's disease.
- To characterize conformational changes induced by MLi-2 and PD mutations in LRRK2.
Main Methods:
- Utilized a multitiered approach including hydrogen-deuterium exchange mass spectrometry (HDX-MS) and molecular dynamics (MD) simulations.
- Mimicked LRRK2 activation by deleting N-terminal domains and studied the effects of the kinase inhibitor MLi-2.
Main Results:
- MLi-2 binding reduces solvent accessibility across LRRK2, suggesting conformational stabilization.
- MD simulations revealed the dynamic consequences of kinase domain mutations on LRRK2 structure.
- The kinase domain, particularly the DYGψ motif, was identified as the central allosteric hub for LRRK2 regulation.
Conclusions:
- Parkinson's disease-associated LRRK2 mutations hijack its activation pathway, primarily through alterations in the kinase domain.
- The kinase domain acts as a critical allosteric regulator, making it a potential therapeutic target for Parkinson's disease.
Related Concept Videos
01:26Receptor Tyrosine Kinases
01:22PI3K/mTOR/AKT Signaling Pathway
01:22Amplifying Signals via Enzymatic Cascade
01:30Assembly of Signaling Complexes
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
01:16Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
01:07MAPK Signaling Cascades